JUN 17, 2019 7:22 AM PDT

Drug Delays Type 1 Diabetes in High Risk Individuals

WRITTEN BY: Nouran Amin

An immunotherapeutic, involving anti-CD3 monoclonal antibody (teplizumab), was seen to slow down the progression to clinical type 1 diabetes in high risk individuals. Findings from the National Institutes of Health-funded research show that clinical type 1 diabetes can be delayed by two or more years for individuals at high risk.

"The difference in outcomes was striking. This discovery is the first evidence we've seen that clinical type 1 diabetes can be delayed with early preventive treatment," said Lisa Spain, Ph.D., Project Scientist from the NIH's National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), sponsor of TrialNet. "The results have important implications for people, particularly youth, who have relatives with the disease, as these individuals may be at high risk and benefit from early screening and treatment."

These results were published online in The New England Journal of Medicine and presented at the American Diabetes Association Scientific Sessions in San Francisco.

"Previous clinical research funded by the NIH found that teplizumab effectively slows the loss of beta cells in people with recent onset clinical type 1 diabetes, but the drug had never been tested in people who did not have clinical disease," said Kevan C. Herold, M.D., of Yale University, the study's lead author. "We wanted to see whether early intervention would have a benefit for people who are at high risk but do not yet have symptoms of type 1 diabetes."

Type 1 diabetes is a result of the immune system attacking its own insulin-producing cells. Insulin is critical for converting glucose into energy. However, with Teplizumab, it works by targeting the cells that recognize the insulin producing cells as ‘foreign’—lessening the destruction.

Learn more about Type 1 Diabetes:

"While the results are encouraging, more research needs to be done to address the trial's limitations, as well as to fully understand the mechanisms of action, long-term efficacy and safety of the treatment," said Dr. Spain.

"This trial illustrates how decades of research on the biology of type 1 diabetes can lead to promising treatments that have a real impact on people's lives. We're very excited to see the next steps in this research," said Dr. Griffin P. Rodgers, NIDDK Director. "The dedicated researchers, volunteers and families participating in this program make discoveries like this possible."

Source: National Institutes of Health

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 25, 2020
Cancer
Using Transcription Factors to Predict Bladder Cancer Prognosis
MAY 25, 2020
Using Transcription Factors to Predict Bladder Cancer Prognosis
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, wi ...
MAY 14, 2020
Drug Discovery & Development
Therapeutic for Gastrointestinal Tumors
MAY 14, 2020
Therapeutic for Gastrointestinal Tumors
The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal ...
JUN 11, 2020
Cancer
Fighting Cancer Stem Cells with Combination Therapy
JUN 11, 2020
Fighting Cancer Stem Cells with Combination Therapy
Pancreatic cancer is one of the most fatal cancers in the United States and is rapidly advancing up the ranks. The best ...
JUN 18, 2020
Drug Discovery & Development
FDA Cancels Emergency Approval for Hydroxychloroquine
JUN 18, 2020
FDA Cancels Emergency Approval for Hydroxychloroquine
The US Food and Drug Administration (FDA) has decided to cancel emergency use authorization for Hydroxychloroquine and C ...
JUN 26, 2020
Drug Discovery & Development
Bacterial Virus May Treat and Prevent COVID-19 Infections
JUN 26, 2020
Bacterial Virus May Treat and Prevent COVID-19 Infections
Researchers say that a type of virus known to infect bacteria could be used to treat and prevent COVID-19 bacterial infe ...
JUL 05, 2020
Microbiology
Stimulating Antibiotic Production in Bacteria
JUL 05, 2020
Stimulating Antibiotic Production in Bacteria
The microorganisms of the world have to compete for survival, and they sometimes do battle with one another. Some use an ...
Loading Comments...